Investors

Investor Overview

Synta Overview

Our mission at Synta is to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. We aim to create the best place for the best people to create breakthrough drugs that change medical... More >>

Recent NewsMore >>
DateTitle 
07/21/14Synta Announces Advancement of Ganetespib into Phase 3 Extension of AML LI-1 Study for Patients with AML and High-Risk MDS
- Follows Positive Interim Analysis of Phase 2 Results - - First of Three Randomized Studies Sponsored by Cardiff University and Supported by the Leukemia & Lymphoma Research Fund and Cancer Research UK to Include Ganetespib - LEXINGTON, Mass.--(BUSINESS WIRE)--Jul. 21, 2014-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the advancement of ganetespib into the Phase 3 extension of the AML LI-1 (less intensive) trial. A... 
Printer Friendly Version
06/19/14Synta to Present at the 9th Annual JMP Securities Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Jun. 19, 2014-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will present at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25, at 2:30 p.m. (EDT) in New York. A live audio webcast and replay of the presentation will be available on the "Investors" section of the Company's website, www.syntapharma.com. About Synta Pharmaceuticals ... 
Printer Friendly Version
05/29/14Synta to Present at the Jefferies 2014 Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--May 29, 2014-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will present at the Jefferies 2014 Global Healthcare Conference on Thursday, June 5, at 11:00 a.m. (ET) in New York. A live webcast and replay of the presentation will be available on the "Investors" section of the Company's website, www.syntapharma.com. About Synta Pharmaceuticals Synta Pharm... 
Printer Friendly Version
05/28/14Synta Announces Presentations at the 2014 American Society for Clinical Oncology (ASCO) Annual Meeting
LEXINGTON, Mass.--(BUSINESS WIRE)--May 28, 2014-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced scheduled presentations at the 2014 American Society for Clinical Oncology (ASCO) Annual Meeting, which is taking place May 30 – June 3 in Chicago. GALAXY-2 trial design “GALAXY-2 trial (NCT01798485): A randomized phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung ... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Stock Quote
SNTA (Common)
ExchangeNASDAQ (US Dollar)
Price$4.02
Change (%) Stock is Down 0.03 (0.74%)
Volume1,763,180
Data as of 07/28/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Synta 2013 Form 10-K